BioMarin Pharmaceutical (BMRN) ROE - Return on Equity
Current and historical Return on Equity (ROE) values for BioMarin Pharmaceutical (BMRN) over the last 10 years.
|Medical||Medical - Biomedical and Genetics||$14.285B||$1.314B|
|BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.|